Besides ibrutinib, sufferers with M-CLL, devoid of TP53 aberrations and healthy enough to tolerate FCR therapy, may still be great candidates for that latter, With all the profit staying this cure may be finished in six months when ibrutinib has to be taken indefinitely. This option would be especially worthwhile for non-compliant people or those i